Objectives: To assess the efficacy and safety of abatacept in methotrexate (MTX)-naïve patients with early rheumatoid arthritis (RA) and poor prognostic factors.
Methods: In this double-blind, Phase IIIb study, patients with RA ≤2 years were randomized 1:1 to receive abatacept (~10 mg/kg) plus MTX, or placebo plus MTX. Patients were MTX-naïve and seropositive for rheumatoid factor (RF), anti-cyclic citrullinated protein (CCP) 2 or both, and had radiographic evidence of joint erosions. The co-primary endpoints were the proportion of patients achieving Disease Activity Score (DAS) 28-defined remission (C-reactive protein) and joint damage progression (Genant-modified Sharp total score [TS]) at Year 1. Safety was monitored throughout.
Results: At baseline, patients had a mean DAS28 of 6.3, a mean TS of 7.1 and mean disease duration of 6.5 months; 96.5 and 89.0% of patients were RF or anti-CCP2 seropositive, respectively. At Year 1, a significantly greater proportion of abatacept plus MTX-treated patients achieved remission (41.4 vs 23.3%; p<0.001), and there was significantly less radiographic progression (mean change in TS; 0.63 vs 1.06; p=0.040), versus MTX alone. Over 1 year, the frequency of adverse events (AEs; 84.8 vs 83.4%), serious AEs (7.8 vs 7.9%), serious infections (2.0 vs 2.0%), autoimmune disorders (2.3 vs 2.0%) and malignancies (0.4 vs 0%) was comparable for abatacept plus MTX versus MTX alone.
Conclusions: In a MTX-naïve population with early RA and poor prognostic factors, the combination of abatacept and MTX provided significantly better clinical and radiographic efficacy compared with MTX alone, and had a comparable, favorable safety profile.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.